Clinical Trials

264 enrolled

Nasopharyngeal Carcinoma

NCT05340491 2026-05-11

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

212 enrolled

Nasopharyngeal Carcinoma

NCT06323239 2026-05-11

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

148 enrolled

Nasopharyngeal Carcinoma

NCT07555860 2026-04-29

Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

28 enrolled

Phase 3 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07540390 2026-04-22

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

442 enrolled

Phase 1/2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07320963 2026-03-20

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

52 enrolled

Nasopharyngeal Carcinoma

NCT06592599 2026-02-10

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

24 enrolled

Nasopharyngeal Carcinoma

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

300 enrolled

Nasopharyngeal Carcinoma

NCT07136519 2025-08-22

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

30 enrolled

Nasopharyngeal Carcinoma

NCT07110558 2025-08-07

PUPA

59 enrolled

Nasopharyngeal Carcinoma

NCT05147844 2025-07-14

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

NCT06228079 2025-07-04

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

176 enrolled

Nasopharyngeal Carcinoma

NCT06235203 2025-06-03

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

154 enrolled

Nasopharyngeal Carcinoma

NCT06987123 2025-05-23

TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial

62 enrolled

Nasopharyngeal Carcinoma

NCT06912711 2025-05-21

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

70 enrolled

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT04517214 2025-04-02

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

100 enrolled

Nasopharyngeal Carcinoma

NCT06712888 2025-03-18

Navigation

466 enrolled

Nasopharyngeal Carcinoma

NCT06851247 2025-02-28

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

47 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT05869227 2024-12-30

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

166 enrolled

Nasopharyngeal Carcinoma

NCT04996758 2024-12-12

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Phase 2 Completed

Nasopharyngeal Carcinoma, Recurrence

NCT06026878 2023-09-07

GNT Induction Treatment in Locally Advanced NPC

228 enrolled

Nasopharyngeal Carcinoma

NCT05813626 2023-04-14

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

89 enrolled

Nasopharyngeal Carcinoma

NCT05229315 2023-04-13

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

45 enrolled

Nasopharyngeal Carcinoma

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT05484375 2022-08-02

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

Nasopharyngeal Carcinoma

NCT04398056 2022-07-06

Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma

22 enrolled

Nasopharyngeal Carcinoma

NCT04073784 2022-04-26

Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Phase 1 Unknown

41 enrolled

Nasopharyngeal Carcinoma

NCT05341193 2022-04-22

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 1/2 Unknown

32 enrolled

GastrointestinalHead & Neck

Nasopharyngeal Carcinoma

NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Phase 1/2 Unknown

401 enrolled 1 FDA

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

NCT04992988 2021-08-20

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Nasopharyngeal Carcinoma

NCT04376866 2021-07-20

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

204 enrolled

Nasopharyngeal Carcinoma

NCT04778956 2021-03-04

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

218 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT04453813 2020-09-28

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

226 enrolled

Nasopharyngeal Carcinoma

NCT04447326 2020-06-25

Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma

106 enrolled